Amgen Drug Pipeline

Amgen maintains a substantial clinical portfolio, with 656 trials registered since 2008, and 103 currently active programs. These active trials span from Phase 1 through Phase 4, with a notable concentration in Phase 3 development (49 trials). The portfolio covers 15 therapeutic areas, but is heavily weighted toward oncology, which accounts for 46% of active programs (47 trials). Within oncology, the most active indications are Small Cell Lung Cancer (SCLC) with 11 active trials (2 in Phase 3), Advanced Solid Tumors (7 active), Prostate Cancer (7 active, 2 in Phase 3), Non-Small Cell Lung Cancer (NSCLC) with 6 active trials (4 in Phase 3), and Acute Lymphoblastic Leukemia (ALL) with 5 active trials (2 in Phase 3). Beyond oncology, the company has significant activity in Metabolic diseases (13 active trials), Immunology (7 active trials), as well as smaller portfolios in Musculoskeletal, Cardiovascular, and Central Nervous System disorders. The relatively high number of Phase 3 trials suggests a focus on late-stage development and potential near-term product launches.